Medication info
Pregabalin Capsule 75 mg (Pregabalin)

Pregabalin Capsule 75 mg (Pregabalin)

Prescription medicationHard capsuleOral
Ingredient · strength
Pregabalin›75mg / 1 capsule
Manufacturer / importer
IYON Pharmaceutical Co., Ltd.
Appearance
Hard capsules with an upper reddish-brown and lower white color containing a white powder that is white or pale yellow.
Packaging
30 capsules/bottle, 60 capsules/bottle
Approval status
Active

MFDS item code 201601284 · Approved 2016.03.03 · Insurance code 658603440

Summary

Main use
Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy
Who takes it
Adults · Children
Adult dose
This drug is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above formula by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the method of administration. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.
Child dose
7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12 ~17 years because there are insufficient data on safety and efficacy.

Ingredients

Manufacturer
IYON Pharmaceutical Co., Ltd.

Efficacy & effects

Treatment of neuropathic pain and fibromyalgia; adjunctive treatment of partial seizures in epilepsy

  • Peripheral neuropathic pain
  • central neuropathic pain
  • partial seizures
  • fibromyalgia
View approved original text

This medication is used to treat peripheral and central neuropathic pain in adults. Additionally, it serves as an adjunctive treatment for partial seizures in patients with epilepsy, regardless of the presence of secondary generalized symptoms. Furthermore, it is effective for the treatment of fibromyalgia. In summary, it is utilized to improve various neurological disorders and pain conditions.

How to take

Adult dose

This drug is administered orally as pregabalin, in 2 divided doses per day, regardless of food. Since this drug is primarily excreted by the kidneys, the dose should be adjusted in patients with impaired renal function. (See section ‘5. Patients with Renal Impairment’.) 1. Neuropathic Pain 1) Peripheral Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 3 to 7 days. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 2) Central Neuropathic Pain Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. After an additional 1 week, it may be increased to the target daily dose of 600 mg. If the target daily dose is not tolerated, dose reduction may be considered. (See section ‘4. Discontinuation of Treatment’.) 2. Epilepsy Adults: This drug may be administered at an initial dose of 150 mg/day. Based on the response and tolerability of each patient, the dose may be increased to 300 mg/day after 1 week. If necessary, it may thereafter be increased at 7-day intervals to a maximum of 600 mg/day. 3. Fibromyalgia The recommended dose of this drug for fibromyalgia is 300 mg to 450 mg/day. The initial dose is 75 mg twice daily (150 mg/day), and based on efficacy and tolerability, it may be increased within 1 week to 150 mg twice daily (300 mg/day). For patients who do not experience sufficient benefit at a dose of 300 mg/day, the dose may be increased within 1 week to 225 mg twice daily (450 mg/day). Clinical studies have also been conducted at a dose of 600 mg/day, but there is no evidence of additional benefit or adequate tolerability at this dose. In view of dose-dependent adverse reactions, doses exceeding 450 mg/day are not recommended. 4. Discontinuation of Treatment Based on current clinical experience, if treatment with this drug is discontinued, it should be tapered gradually over at least 1 week. 5. Patients with Renal Impairment After entering the systemic circulation, this drug is primarily excreted by the kidneys as unchanged drug. Since the clearance of this drug is directly affected by creatinine clearance, dose reduction in patients with impaired renal function should be individualized based on creatinine clearance. Creatinine clearance [Table 1] is determined using the following formula. *: For women, multiply the result obtained from the above formula by 0.85. This drug is effectively removed from plasma by hemodialysis (approximately 50% within 4 hours). In patients undergoing hemodialysis, the daily dose of pregabalin should be adjusted based on renal function. In addition to the daily dose based on renal function, a supplemental dose should be administered immediately after each 4-hour hemodialysis session. [Table 1]. Pregabalin Dosage Based on Renal Function Creatinine clearance (CLcr), (mL/min) ≥60: Starting dose 150 (mg/day), maximum dose 600 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥30 -<60: Starting dose 75 (mg/day), maximum dose 300 (mg/day), BID or TID Creatinine clearance (CLcr), (mL/min) ≥15 -<30: Starting dose 25-50 (mg/day), maximum dose 150 (mg/day), QD or BID Creatinine clearance (CLcr), (mL/min) <15: Starting dose 25 (mg/day), maximum dose 75 (mg/day), QD Supplemental dose after hemodialysis: 25, 100, single dose b TID = total daily dose administered in 3 divided doses BID = total daily dose administered in 2 divided doses QD = administered once daily a: The total daily dose (mg/day) should be administered in divided doses as specified in the method of administration. b: Supplemental dose refers to an additional dose administered as a single dose. 6. Patients with Hepatic Impairment No dose adjustment is necessary in patients with hepatic impairment. 8. Elderly Patients (aged 65 years or older) Dose reduction may be necessary in elderly patients with impaired renal function.

Child dose

7. Pediatric and adolescent patients Administration is not recommended for children under 12 years of age or adolescent patients aged 12 ~17 years because there are insufficient data on safety and efficacy.

Precautions

This medication may lead to mental changes such as suicidal thoughts, suicidal behaviors, and depression during treatment, so patients and their caregivers should inform healthcare professionals immediately if such symptoms occur. This medication should not be used by patients with allergies to its components or with genetic lactose intolerance issues. Diabetic patients should exercise caution, as weight gain may necessitate dose adjustments of blood sugar control medications. If symptoms of angioedema, such as swelling of the face or around the mouth occur during the treatment, the medication should be discontinued immediately. Elderly patients may experience dizziness or drowsiness, increasing their risk of falls and injuries, hence caution is necessary. Temporary blurred vision or changes in vision may occur, and if symptoms are severe, discontinuation of the medication may be helpful. Abrupt discontinuation of this medication may lead to withdrawal symptoms such as insomnia, headache, nausea, and anxiety, thus tapering should be discussed with a healthcare professional. Due to the risk of drug abuse, patients with a history of substance abuse should particularly take care when using this medication, and should report any unusual behavior to healthcare professionals. Patients with impaired kidney function may require dose adjustments. Caution is advised when used in patients with severe heart disease, as well as in older adults or patients with impaired respiratory function. This medication may cause drowsiness and dizziness; hence dangerous activities such as driving or operating machinery should be avoided until symptoms are confirmed. In early pregnancy, it may affect the fetus, so pregnant women should refrain from using it if possible, and women of childbearing age should use effective contraception. During breastfeeding, this medication may be transmitted through breast milk, and the risks and benefits of using this medication while breastfeeding should be discussed with a healthcare professional. The likelihood of pharmacokinetic interactions with other drugs is low, however, co-administration with central nervous system depressants or opioid analgesics may increase the risk of respiratory depression. In case of overdose, symptoms such as confusion, drowsiness, and depression may occur, and treatments such as hemodialysis may be required if necessary. Keep out of reach of children, and transferring to other containers can negatively affect quality, so caution is required.

Side effects

suicidal ideation, suicidal behavior, depression, abnormal changes in mood and behavior, angioedema, facial swelling, perioral swelling, upper airway swelling, dizziness, drowsiness, loss of consciousness, confusion, mental disorder, blurred vision, vision changes, insomnia, headache, nausea, anxiety, diarrhea, influenza-like illness, restlessness, depression, suicidal thoughts, pain, seizures, hyperhidrosis, misuse, abuse, dependence, weight gain, rhinitis, neutropenia, increased appetite, loss of appetite, hypoglycemia, confusion, disorientation, irritability, depression, euphoria, decreased libido, insomnia, depersonalization, hypersexuality, restlessness, anxiety, mood swings, emotional blunting, emotional elevation, difficulty in finding appropriate terms, hallucinations, abnormal dreams, increased libido, panic attacks, loss of impulse control, apathy, dizziness, drowsiness, ataxia, motor coordination disorders, balance disorders, amnesia, attention deficit, memory impairment, tremors, dysarthria, sensory disturbances, sensory loss, sedation, hypersomnia, cognitive impairment, nystagmus, speech disorders, myoclonus, decreased reflexes, movement abnormalities, psychomotor agitation, positional dizziness, hypersensitivity, burning sensation, tremor at rest, syncope, confusion, motor decline, olfactory abnormalities, loss of taste, writing impairment, blurred vision, diplopia, peripheral vision loss, visual field defects, photophobia, dry eyes, conjunctival swelling, decreased vision, ocular pain, eye fatigue, increased lacrimation, ocular irritation, mydriasis, changes in depth perception during vibration, strabismus, brightness of visual fields, vertigo, auditory hypersensitivity, first-degree AV block, tachycardia, sinus bradycardia, sinus tachycardia, sinus arrhythmia, hypotension, hypertension, flushing, facial redness, peripheral coldness, dyspnea, epistaxis, cough, nasal congestion, rhinitis, snoring, throat tension, nasal dryness, respiratory depression, vomiting, abdominal distension, constipation, dry mouth, bloating, excessive salivation, gastroesophageal reflux disease, oral sensory loss, ascites, dysphagia, pancreatitis, sweating, papular rash, urticaria, cold sweats, muscle cramps, arthralgia, back pain, limb pain, cervical spasms, joint swelling, myalgia, muscle spasms, throat pain, muscle rigidity, rhabdomyolysis, urinary disorders, urinary incontinence, reduced urine output, renal failure, erectile dysfunction, delayed ejaculation, sexual dysfunction, dysmenorrhea, amenorrhea, breast pain, nipple discharge, gynecomastia, peripheral edema, edema, gait abnormalities, falling, feeling intoxicated, paresthesia, fatigue, chest tightness, generalized edema, pain, fever, chills, weakness, thirst, weight gain, increased alanine aminotransferase, increased creatine phosphokinase in blood, increased aspartate aminotransferase, increased blood glucose, decreased platelet count, decreased potassium in blood, weight loss, increased serum creatinine, decreased white blood cell count, hypersensitivity, allergic reactions, headache, keratitis, congestive heart failure, pulmonary edema, nausea, diarrhea, tongue swelling, itching, Stevens-Johnson syndrome, toxic epidermal necrolysis, urinary retention, gynecomastia, malaise, shock, anaphylaxis-like symptoms, mucocutaneous syndrome, erythema multiforme, delirium, paralysis, affective disorder, drowsiness, state of confusion, depression, agitation, restlessness, seizures

Not everyone experiences these, and they can vary from person to person.

Storage

This medication should be stored in a tightly closed container to avoid exposure to air or moisture, and it is safe to store it at room temperature between 15 to 30 degrees Celsius.

Appearance and packaging

Appearance

Hard capsules with an upper reddish-brown and lower white color containing a white powder that is white or pale yellow.

Package unit

30 capsules/bottle, 60 capsules/bottle

Same-ingredient medicines

Even with the same ingredient, strength, dosage form and how it is taken can differ.

Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.

Questions about this medicine

No questions yet.

For anything that needs medical judgment, consult a doctor or pharmacist.

Related searches

Search tags

Suggested searches

This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.